EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Replimune Group's enterprise value is $3.57 Mil.
Replimune Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-200.44 Mil. Therefore, Replimune Group's EV-to-EBITDA for today is -0.02.
The historical rank and industry rank for Replimune Group's EV-to-EBITDA or its related term are showing as below:
REPL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.75 Med: 0 Max: 0.39
Current: -0.02
During the past 7 years, the highest EV-to-EBITDA of Replimune Group was 0.39. The lowest was -18.75. And the median was 0.00.
REPL's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs REPL: -0.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Replimune Group's stock price is $6.41.
Replimune Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.160. Therefore, Replimune Group's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Replimune Group EV-to-EBITDA Historical Data
The historical data trend for Replimune Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Replimune Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Replimune Group EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Replimune Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Replimune Group's EV-to-EBITDA falls into.
Replimune Group EV-to-EBITDA Calculation
Replimune Group's EV-to-EBITDA for today is calculated as:
Replimune Group's current Enterprise Value is $3.57 Mil.
Replimune Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-200.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Replimune Group (NAS:REPL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Replimune Group's PE Ratio for today is calculated as:
Replimune Group's share price for today is $6.41.
Replimune Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.160.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Replimune Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Replimune Group (Replimune Group) Business Description
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REPL has been successfully added to your 